The Non-Invasive Revolution Reshaping Colorectal Cancer Screening

Colorectal cancer screening is becoming increasingly multimodal. Colonoscopy remains the most definitive colorectal cancer screening test, uniquely combining detection with the ability to identify and remove precancerous lesions during the same procedure. Among current screening modalities, it is the only one that can directly prevent colorectal cancer through polyp removal.

But the screening pathway around colonoscopy is changing rapidly.

Between 2024 and 2026, new stool- and blood-based tests received FDA approval. The American Cancer Society and NCCN expanded their recommendations. Medicare coverage broadened. Abbott completed its $21 billion acquisition of Exact Sciences.

At the same time, the clinical need remains substantial. Colorectal cancer is now the leading cause of cancer death among U.S. adults under 50, and roughly one-third of screening-eligible adults remain inadequately screened.

The result is not a simple shift away from colonoscopy.

It is the emergence of a more complex, multimodal screening ecosystem. One in which colonoscopy, FIT, stool DNA, stool RNA, blood-based testing, and multi-cancer early detection may each serve a distinct role.


As screening options expand, where does each modality truly fit?

Scope Forward’s latest Market Research Report provides an in-depth analysis of the clinical evidence, regulation, reimbursement, economics, competitive landscape, and emerging technologies redefining colorectal cancer screening.

John Allen, MD

Past President, American Gastroenterological Association
Retired Chief Clinical Officer, University of Michigan Medical Group

"This report is one of the most comprehensive analyses of the rapidly changing field of colon cancer detection. Anyone interested in understanding the emerging blood and stool tests now available to detect colon cancer should read this report carefully.  The traditional stance of colonoscopy only is no longer tenable, but gastroenterologists should understand the challenges of non-invasive screening.  Particular emphasis must be on educating our colleagues and patients about the need for follow up colonoscopy after a positive non invasive tests and the benefits of having a portfolio of options for eligible populations. Truly a magnificent work."

What This Report Examines

  • The evolving clinical hierarchy — how colonoscopy, FIT, stool DNA, stool RNA, blood-based testing, CT colonography, and MCED compare across cancer detection, advanced precancer detection, specificity, screening interval, adherence, and preventive value.
  • The emerging diagnostic landscape — including Exact Sciences/Abbott, Geneoscopy, Guardant Health, Freenome, GRAIL, Universal DX, DELFI, and other emerging platforms.
  • Guidelines and reimbursement — including the 2026 ACS update, NCCN, ASGE, Medicare coverage, and the potential implications of future USPSTF recommendations.
  • Real-world implementation — what can be learned from organized screening programs in the Netherlands, Italy, South Korea, Kaiser Permanente, and other health systems.
  • The next generation of screening — including multi-omics, methylation, microRNA, fragmentomics, artificial intelligence, individualized screening intervals, and emerging approaches aimed at improving detection of advanced precancerous lesions.
  • Implications for gastroenterology practice — patient selection, follow-up pathways, diagnostic colonoscopy demand, capacity planning, EHR integration, and the changing role of the gastroenterologist within a multimodal screening system.

Implications for Gastroenterology

  • A changing role for colonoscopy — broader use of stool- and blood-based screening may reduce some routine first-line screening procedures while increasing diagnostic and therapeutic colonoscopies in patients already enriched for pathology.
  • Greater importance of patient selection — gastroenterologists will need to help distinguish which patients are best served by colonoscopy, stool-based testing, blood-based screening, or more intensive evaluation based on risk.
  • Follow-up becomes a clinical priority — every positive non-invasive test ultimately depends on timely colonoscopy, making navigation, tracking, scheduling, and diagnostic resolution increasingly important measures of screening quality.
  • Endoscopy capacity may need to be used differently — emerging modeling suggests that better allocation of existing colonoscopy capacity, rather than simply expanding procedure volume, could improve cancer detection and prevention while increasing the yield of procedures performed.
  • Closer coordination across the screening pathway — as primary care increasingly initiates stool- and blood-based screening, GI practices will need stronger referral pathways, EHR integration, patient counseling, and communication around positive results and surveillance.

The Next Era of CRC Screening Will Be an Ecosystem

Colorectal cancer screening is moving beyond a choice between colonoscopy and non-invasive alternatives. It is becoming an interconnected ecosystem of endoscopy, stool- and blood-based testing, molecular diagnostics, reimbursement, navigation, and risk stratification.

No single modality will define what comes next. How they work together will.

For gastroenterologists, the decisions being made now—who gets which test, how positive results reach colonoscopy, and how capacity and new technologies are integrated—will shape both patient outcomes and the future role of GI practice.

This report helps you understand the emerging system before it reshapes clinical practice.

The future of CRC screening is not colonoscopy versus non-invasive testing.

It is a system that expands who gets screened, preserves the ability to prevent cancer, and ensures every positive test reaches colonoscopy.